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refractory lower gastrointestinal hemorrhage in a
patient with recently implanted mechanical valve:
a case report
Amr S Omar1,2*, Suraj Sudarsanan1, Hesham Ewila1,3 and Ali Kindawi1Abstract
Background: Bleeding is a common complication after cardiac surgery. However, lower gastrointestinal bleeding is
not usually associated with this type of surgery.
Case presentation: A 50-year-old man with a history of aortic regurgitation underwent elective mechanical valve
replacement under cardiopulmonary bypass. He experienced a complicated intraoperative course involving
unexplained cardiac arrest following induction of anesthesia. He also developed two episodes of massive lower
gastrointestinal bleeding secondary to mucosal ischemia while convalescing in the cardiothoracic surgery intensive
care unit. After unsuccessful attempts to control the bleeding, exhaustion of blood products, and consideration of
the high risk of mortality associated with surgery and the possibility of early- and long-term surgical complications,
the decision was made to administer two successive doses of recombinant activated factor VII at 60 mcg/kg.
Hemostasis was achieved without adverse systemic or valvular effects.
Conclusions: A favorable outcome was achieved after administration of recombinant activated factor VII, which
controlled the patient’s severe lower gastrointestinal bleeding. This outcome suggests the need to raise awareness
about the use of this drug in dire circumstances when other conventional measures fail or are unsuitable.
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Postoperative bleeding is a major cause of mortality and
increased length of stay in the intensive care unit (ICU).
Bleeding after valvular or other complex cardiac sur-
geries is caused by thrombocytopenia or defects in plate-
let function after cardiopulmonary bypass and, rarely,
disseminated intravascular coagulation and deficiencies
in clotting factors. Even patients without clotting dis-
orders who are subjected to cardiac surgery may develop
difficult-to-control bleeding, especially patients under-
going re-do cardiac surgery or in whom the cardiac
tissue is damaged or friable. Mediastinal bleeding after
valve surgery may be controlled with administration of* Correspondence: a_s_omar@yahoo.com
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unless otherwise stated.recombinant activated factor VII (rFVIIa) when conven-
tional products fail [1,2]. Lower gastrointestinal bleeding
(LGIB) is anatomically defined as hemorrhage occurring
distal to the ligament of Treitz [3]. Massive LGIB is
usually associated with a high mortality rate. The most
frequent causes of LGIB are vascular malformation, tu-
mors, and particularly colonic diverticulosis, which may
be asymptomatic or involve perforation and massive
bleeding necessitating emergency colectomy [4]. Massive
LGIB may be associated with high mortality, especially
when occurring in elderly patients [4]. The sigmoid colon
is a common site for this disease, but the pathology
remains poorly understood [4]. Recombinant activa-
ted factor VII (rFVIIa) (NovoSeven; Novo Nordisk A/S,
Copenhagen, Denmark) has been used in the management
of LGIB [4-6]. However, there are no previous reports oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Sigmoidoscopy showing a large hematoma in the
cecum.
Figure 2 Sigmoidoscopy showing multiple ulcerations in the
ascending colon.
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have recently undergone mechanical valve implantation.
We herein report a case of massive LGIB after the
completion of a complicated valvular cardiac surgery.
Administration of rFVIIa controlled the bleeding. The
use of rFVIIa was a desperate measure after the exhaus-
tion of blood products and failure to control the blee-
ding with other drugs.
Case presentation
A 50-year-old man was admitted for elective aortic valve
replacement. The patient had severe aortic regurgitation;
however, apart from hypertension, he had no other sys-
temic diseases. The patient’s electrocardiogram showed a
right bundle branch block with sinus bradycardia. Echo-
cardiography revealed an ejection fraction of 45% to 55%,
severe aortic valve regurgitation, and a dilated left ven-
tricle. He had a normal preoperative coronary angiogram.
Immediately after routine induction of anesthesia, the
patient developed intraoperative cardiac arrest. Car-
diopulmonary resuscitation was started by performing
emergency cardiopulmonary bypass, and the aortic valve
was replaced with a mechanical valve. Postoperatively,
the patient’s hemodynamic parameters were unstable
and he was transferred to the ICU on inotropic support,
atrioventricular sequential pacing, and an intra-aortic
balloon pump. During the ICU stay, the patient deve-
loped acute kidney injury with hepatic dysfunction and
deranged coagulation requiring massive transfusion of
blood and blood products in the first 48 hours postope-
ratively. Regular hemodialysis was initiated from the first
postoperative day. By the fourth postoperative day, his
renal, hepatic, and coagulation profiles had improved to-
ward the reference ranges. An anticoagulation regimen
of heparin and oral warfarin was started. Because of his
depressed level of consciousness and inability to be
weaned off mechanical ventilation, the patient under-
went percutaneous tracheostomy on the seventh post-
operative day. He gradually recovered in the ICU. On
the 16th postoperative day, however, he developed fresh
rectal bleeding. Urgent colonoscopy revealed multiple
ischemic ulcers in the colon and a large hematoma in
the right colon (Figures 1 and 2). The anticoagulants
were stopped and consultation was requested with a
gastrointestinal surgeon. The surgeon felt that in light of
the patient’s poor general condition, extensive disease,
and likely dismal outcome of pancolectomy, surgical in-
tervention was not warranted. The patient remained
stable over the next few days and was weaned from the
ventilator. Upon reinstitution of anticoagulants on the
24th postoperative day, he developed massive LGIB of
approximately 6 L in the form of melena. He also exhi-
bited hemodynamic compromise necessitating reintro-
duction of vasopressors and mechanical ventilation. Hewas transfused aggressively with 12 units of packed red
blood cells, 14 units of fresh frozen plasma, 12 units of
platelet concentrate, and fibrinogen. The bleeding con-
tinued unabated despite correcting the coagulopathy. A
consensus was thus reached among the intensivist,
hematologist, primary cardiac surgeon, and gastroin-
testinal surgeon to administer rFVIIa. The patient was
given 60 mcg/kg of rFVIIa as a first administration after
failure of standard treatment, which resulted in prompt
cessation of bleeding. He remained stable for the next
48 hours. On the 26th postoperative day, he developed
another bout of melena (approximately 2 L). After the
coagulation parameters had been corrected, a similar
dose of rFVIIa was administered. This stopped the
bleeding, and the patient gradually recovered. His antic-
oagulation treatment regimen was resumed after 1 week,
and he had no further episodes of bleeding. His pros-
thetic valve function was monitored with regular trans-
thoracic echocardiography throughout these periods of
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longed by supervening sepsis. He was treated with colis-
tin for Acinetobacter baumannii identified in the urine
and with meropenem for Enterobacter cloacae in the
sputum; he gradually improved upon prompt adminis-
tration of these antimicrobials. The patient was finally
transferred out of the ICU on the 45th postoperative day
after full functional recovery and was discharged from
the hospital after another week of convalescence in the
surgical step-down unit. Since discharge, he has been
followed regularly in the warfarin clinic for adjustment
of his anticoagulant dose. Repeat colonoscopy after
3 months revealed healing ulcers with no evidence of
further bleeding episodes. The patient’s laboratory values
before and after administration of rFVIIa are noted in
Table 1.
Approved by the Institutional Research Ethics Committee
of Hamad Medical Corporation State of Qatar (proto-
col #13347/13).
Discussion
The drug rFVIIa was developed to treat patients with
congenital hemophilia or inhibition of factor VIII or IX.
Multiple individual case reports have described the suc-
cessful use of rFVIIa as a hemostatic drug in the setting
of uncontrolled bleeding, even without preexisting co-
agulopathy [7-9]. Its mechanism of action involves en-
hancing hemostasis at the site of injury where tissue
factor is produced without systemic activation of the co-
agulation cascade. At pharmacologic levels, rFVIIa forms
a complex with tissue factor from the subendothelium
and on the surface of cells at the site of tissue damage.
rFVIIa also binds to the surface of activated platelets.
Factor X is activated by rFVIIa–tissue factor complex
and rFVIIa on the surface of platelets, to FXa, whichTable 1 Patient laboratory value before and after administrat
On admission Before 1st bleeding episode 24 hou
Creatinine 96 763 639
Hb 14.8 7.6 10.1
Hematocrite 44.5 20.9 29.5
Platelets 190 90 104
WBCs 8 7.2 8.7
RBCs 5.4 2.5 3.4
PTT 34.4 32.8 30.1
INR 1.1 1.6 1.1
Fibronegen 1.7 2.74
D-Dimer 4.31 2.53
Na 137 138 145
K 4.5 4.9 3.7
Ca ++ 2.1 2.18 2.41complexes with FVa to catalyze the conversion of pro-
thrombin to thrombin. In addition, rFVIIa has been used
to treat diverse congenital and acquired hemostatic disor-
ders with variable rates of success [4]. Its hemostatic
mechanism of action is attributed either to activation of
thrombin by endogenous tissue factor, which is a site-
specific procoagulant action, or to activation of factor X,
which binds to platelets without tissue factor, leading to
thrombin formation when a large amount of rFVIIa is
administered. Thrombin activation leads to fibrin sta-
bilization and fibrin degradation inhibition [7]. The
success of rFVIIa as a curative therapy has been demon-
strated in many case reports in which hemostasis was
achieved in patients with life-threatening LGIB [5], and it
has been used successfully to control mediastinal bleeding
after cardiac surgery [7,8].
The use of cardiopulmonary bypass in valve replace-
ment and coronary artery bypass graft surgery may be
complicated by excessive bleeding [9]. This cannot explain
the bleeding in our patient because he did not exhibit
significant mediastinal bleeding and because his LGIB oc-
curred late in the course. However, ischemia, age, and ath-
erosclerosis may explain such an event [4].
While rFVIIa has been reported to control life-
threatening colonic bleeding, to our knowledge it has never
been used in a patient with a recently implanted mechan-
ical cardiac prosthetic valve, which confers additional risk.
The potential advantage of rFVIIa in patients with LGIB is
that it offsets the high-risk surgery undertaken to control
bleeding; up to 43% of patients have no identifiable bleed-
ing point [10,11]. Although a standard dose of rFVIIa has
not been identified, doses of 40, 60, and 90 mcg/kg have
been given in various situations and have produced diffe-
rent outcomes in terms of reduction of bleeding, decreased
use of blood products, and enhanced surgical interventionion of rFVIIa
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ing, we were advised to initiate a moderate dose in the
present case and repeat it if necessary. Some practitioners
have advocated repeated administration after 6 hours for
clot stabilization [5,12], but this was not needed in our
patient. Because of the high cost of rFVIIa, a pragmatic ap-
proach is required in using this drug; the cost of interven-
tion must be weighed against both the relative risk and
burden on the blood bank. Complications associated with
the use of rFVIIa include thrombosis, which had an inci-
dence as high as 13.8% in one report [13], and increased
mortality. The risk of thrombosis was higher in our patient
because of the existing mechanical valve. Postoperative ob-
struction and thrombosis of the valve are not uncommon,
occurring at rates of 0.3% to 1.3% and as high as 10% in
nonobstructive thrombosis, respectively [14]. Mechanical
valves are usually associated with a lower rate of throm-
bosis than are bioprosthetic valves, but still carry a risk.
This risk can be reduced with appropriate anticoagulation
[15]. Because surgical intervention in the present critically
ill patient carried a high risk of mortality, we used rFVIIa
as a rescue measure when routinely used blood products
failed to stop the bleeding and alternatives were limited.
The relatively high cost of rFVIIa mandates its proper use;
notably, it is licensed to be used in patients with he-
mophilia, and its use outside this spectrum is considered
to be off-label [12]. It has been argued that the hemostatic
effectiveness of rFVIIa as a therapeutic intervention re-
mains unproven and that clinical trials should guide licen-
sing for indications other than hemophilia [16]. However,
the safety of rFVIIa was investigated in a study by von
Heymann et al. [8] in which no thromboembolic complica-
tions were encountered after administration of this drug to
patients in the study group. This result led the authors to
acknowledge the safety of last-resort therapy with rFVIIa,
but not to support its routine use when conventional ther-
apy is available [8]. Moreover, a local procoagulant effect
of rFVIIa without activation of the systemic coagulation
cascade has been mentioned in several studies [17,18].
These studies found that rFVIIa may provide effective
hemostasis by acting locally at the site of vessel damage,
where it combines with tissue factor to generate thrombin.
Conclusion
A favorable outcome was achieved after the administra-
tion of rFVIIa to control severe LGIB after running out of
options in a clinically deteriorating patient. This point to
the need to raise awareness about the use of this drug as a
last resort desperate measure to control bleeding which
persists despite conventional management.
Key messages
A coincidental association between massive LGIB and
cardiac surgery is possible. The postoperative period ofcardiac surgery may preclude surgical interventions for
bleeding. rFVIIa has emerged as an effective therapeutic
option in such circumstances. rFVIIa seems to be a safe
option for controlling LGIB in patients with recently
implanted mechanical heart valves because of its local
procoagulant action. More detailed studies should be
undertaken before this agent can be used routinely as
first-line therapy in such instances. In the meantime,
rFVIIa should be used as a last resort to control bleeding
when all other options have been exhausted.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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